News & Events

BioCentury, The Bernstein Report on BioBusiness, February 8, 2010

Altair: Breathing easier with antisense (PDF 60k)

Business Wire, San Diego Daily Transcript, BioSpace, AlphaTrade and CNBC,
November 19, 2009

Altair Therapeutics Announces Commencement of a Multi-Center
Phase IIa Clinical Trial of Inhaled AIR645 to Treat Asthma.
Study to Assess Efficacy of Once-Weekly Inhaled Non-Steroidal Anti-Inflammatory
in Suppressing Asthmatic Response

Business Wire, Fierce Biotech, Xconomy, SocalTECH.com, RTT News Global Financial News Wire, San Diego Business Journal, Genetic Engineering News, ALT Assets - Private Equity News, BioCentury, Dow Jones, BioWorld Today and SCRIP News, November 11, 2009 »

Altair Therapeutics Secures $17 Million Financing
Round to fund phase 2a clinical trials for lead candidate AIR645, advance R&D

Reuters, PharmaLive, San Diego Daily Transcript, BioSpace, BioPortfolio (U.K.) and Pipeline Review,
September 14, 2009 »

Altair Therapeutics Reports Successful Phase 1 Study of Inhaled AIR645
Data Shows Safety and Tolerability of First-in-Class Dual IL-4/IL-13 Inhibitor with Pharmacokinetics Supporting Once-Weekly Asthma Treatment

San Diego Business Journal, June 29, 2009 »

Biotech Profile - Joel Martin.
By: San Diego Business Journal Staff

BioCentury, May 25, 2009 »

Data from a double-blind, placebo-controlled, single and multiple dose, Canadian Phase I trial (AIR645-CSI) in 72 evaluable healthy volunteers showed that nebulized AIR645 was well tolerated and had dose-dependent exposure in the airways.

Announcement, May 21, 2009 »

Altair Therapeutics will be presenting at the European Respiratory Society (ERS),
Annual Congress 2009 in Vienna, Austria. September 12-16.

BioSpace, May 18, 2009 »

Altair Therapeutics Reports Successful Completion of Phase 1 Study of Inhaled AIR645.
Data Shows Safety and Tolerability of First-in-Class Dual IL-4/IL-13 Inhibitor with Pharmacokinetics Supporting Once-Weekly Asthma Treatment

Announcement, ATS 2009 International Conference, May 18, 2009

Altair Therapeutics, Inc. to present a summary of results from its Phase I clinical trial of inhaled AIR645 in healthy volunteers at the American Thoracic Society 2009 International Conference, May 18, 2009 at the San Diego Convention Center in San Diego, California. The oral presentation, entitled, "Randomized, Double-blind, Placebo Controlled First in Human Study of Inhaled AIR645, an IL-4Ralpha Oligonucleotide, in Healthy Volunteers" is scheduled for 2:20-2:35PM within the Mini-Symposium "New Treatment Approaches for Asthma and Allergy."

SAN DIEGO (Business Wire), May 14, 2009 »

Altair Therapeutics Appoints Dr. Joel Martin President and CEO
Industry Veteran to Lead Biopharmaceutical Company Developing Novel Therapeutics for Respiratory Diseases

SAN DIEGO (Business Wire) »

Forward Ventures announced today that it has joined the syndicate for Altair Therapeutics, Inc., a new venture capital funded biotechnology company created to focus on the discovery, development and commercialization of antisense drugs to treat asthma and other respiratory conditions.

BioSpace, October 16, 2007»

ISIS Pharmaceuticals, Inc and Thomas McNerney & Partners Announce Plans for Newly Formed Altair Therapeutics.